Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Immunol ; 197(8): 3099-3110, 2016 10 15.
Article in English | MEDLINE | ID: mdl-27605008

ABSTRACT

Upregulation and/or maintenance of regulatory T cells (Tregs) during autoimmune insults may have therapeutic efficacy in autoimmune diseases. Earlier we have reported that sodium benzoate (NaB), a metabolite of cinnamon and a Food and Drug Administration-approved drug against urea cycle disorders, upregulates Tregs and protects mice from experimental allergic encephalomyelitis, an animal model of multiple sclerosis. However, mechanisms by which NaB increases Tregs are poorly understood. Because TGF-ß is an important inducer of Tregs, we examined the effect of NaB on the status of TGF-ß. In this study, we demonstrated that NaB induced the expression of TGF-ß mRNA and protein in normal as well as proteolipid protein-primed splenocytes. The presence of a consensus STAT6 binding site in the promoter of the TGF-ß gene, activation of STAT6 in splenocytes by NaB, recruitment of STAT6 to the TGF-ß promoter by NaB, and abrogation of NaB-induced expression of TGF-ß in splenocytes by small interfering RNA knockdown of STAT6 suggest that NaB induces the expression of TGF-ß via activation of STAT6. Furthermore, we demonstrated that blocking of TGF-ß by neutralizing Abs abrogated NaB-mediated protection of Tregs and experimental allergic encephalomyelitis. These studies identify a new function of NaB in upregulating TGF-ß via activation of STAT6, which may be beneficial in MS patients.


Subject(s)
Encephalomyelitis, Autoimmune, Experimental/immunology , Food Preservatives/therapeutic use , Multiple Sclerosis/immunology , STAT6 Transcription Factor/metabolism , Sodium Benzoate/therapeutic use , T-Lymphocytes, Regulatory/drug effects , Transforming Growth Factor beta/metabolism , Animals , Antibodies, Blocking/administration & dosage , Cells, Cultured , Cinnamomum zeylanicum/metabolism , Encephalomyelitis, Autoimmune, Experimental/therapy , Female , Forkhead Transcription Factors/metabolism , Humans , Mice , Mice, Inbred C57BL , Mice, Transgenic , Multiple Sclerosis/therapy , Myelin Proteolipid Protein/immunology , Peptide Fragments/immunology , Promoter Regions, Genetic/genetics , STAT6 Transcription Factor/genetics , Sodium Benzoate/metabolism , T-Lymphocytes, Regulatory/immunology , Transforming Growth Factor beta/genetics , Up-Regulation
2.
Int Immunopharmacol ; 35: 217-225, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27082997

ABSTRACT

Infiltration of activated neutrophils into the vital organs contributes to the multiple organ dysfunctions in sepsis. In the present study, we investigated the effects of berberine in combination with yohimbine (BY) on neutrophil tissue infiltration and multiple organ damage during sepsis, and further elucidated the involved mechanisms. Sepsis was induced in mice by cecal ligation and puncture (CLP). BY or CCR2 antagonist was administered 2h after CLP, and anti-IL-10 antibody (IL-10 Ab) or control IgG was injected intraperitoneally just before BY treatment. We found that IL-10 production was enhanced by BY therapy in septic mice. BY significantly attenuated neutrophil tissue infiltration and multiple organ injury in CLP-challenged mice, all of which were completely reversed by IL-10 Ab pretreatment. The levels of KC, MCP-1, MIP-1α and MIP-2 in the lung, liver and kidney were markedly increased 6h after CLP. BY reduced the tissue concentrations of these chemokines in septic mice, but IL-10 Ab pretreatment did not completely eliminate these inhibitory effects of BY. Particularly, dramatically increased CCR2 expression in circulating neutrophils of septic mice was reduced by BY and this effect was completely abolished by IL-10 Ab pretreatment. Furthermore, CCR2 antagonist also inhibited lung and renal injury and neutrophil infiltration in septic mice. Taken together, our data strongly suggest that BY therapy attenuates neutrophil tissue infiltration and multiple organ injury in septic mice, at least in part, via IL-10-mediated inhibition of CCR2 expression in circulating neutrophils.


Subject(s)
Berberine/therapeutic use , Interleukin-10/metabolism , Multiple Organ Failure/drug therapy , Neutrophils/drug effects , Receptors, CCR2/metabolism , Sepsis/drug therapy , Yohimbine/therapeutic use , Animals , Antibodies, Blocking/administration & dosage , Cecum/surgery , Cell Movement/drug effects , Cells, Cultured , Disease Models, Animal , Drug Therapy, Combination , Humans , Interleukin-10/immunology , Male , Mice , Mice, Inbred Strains , Neutrophils/physiology , Receptors, CCR2/genetics
3.
Pain Physician ; 18(4): E615-28, 2015.
Article in English | MEDLINE | ID: mdl-26218952

ABSTRACT

BACKGROUND: Chronic pancreatitis (CP) is a long-standing inflammation of the exocrine pancreas, which typically results in severe and constant abdominal pain. Previous studies on the mechanisms underlying CP-induced pain have primarily focused on the peripheral nociceptive system. A role for a central mechanism in the mediation or modulation of abdominal pain is largely unknown. Tanshinone IIA (TSN IIA), an active component of the traditional Chinese medicine Danshen, exhibits anti-inflammatory properties via downregulation of the expression of high-mobility group protein B1 (HMGB1), a late proinflammatory cytokine. HMGB1 binds and activates toll-like receptor 4 (TLR4) to induce spinal astrocyte activation and proinflammatory cytokine release in neuropathic pain. OBJECTIVE: In this study, we investigated the effect of TSN IIA on pain responses in rats with trinitrobenzene sulfonic acid (TNBS)-induced CP. The roles of central mechanisms in the mediation or modulation of CP were also investigated. STUDY DESIGN: A randomized, double-blind, placebo-controlled animal trial. METHODS: CP was induced in rats by intrapancreatic infusion of trinitrobenzene sulfonic acid (TNBS). Pancreatic histopathological changes were characterized with semi-quantitative scores. The abdomen nociceptive behaviors were assessed with von Frey filaments. The effects of intraperitoneally administered TSN IIA on CP-induced mechanical allodynia were tested. The spinal protein expression of HMGB1 was determined by western blot. The spinal mRNA and protein expression of proinflammatory cytokines IL-1ß, TNF-α, and IL-6 were determined by RT-PCR and western blot, respectively. The spinal expression of the HMGB1 receptor TRL4 and the astrocyte activation marker glial fibrillary acidic protein (GFAP) were determined by western blot or immunohistological staining after intraperitoneal injection of TSN IIA or intrathecal administration of a neutralizing anti-HMGB1 antibody. RESULTS: TNBS infusion resulted in pancreatic histopathological changes of chronic pancreatitis and mechanical allodynia in rats. TSN IIA significantly attenuated TNBS-induced mechanical allodynia in a dose-dependent manner. TNBS significantly increased the spinal expression of HMGB1 and proinflammatory cytokines IL-1ß, TNF-α, and IL-6. These TNBS-induced changes were significantly inhibited by TSN IIA in a dose-dependent manner. Furthermore, TSN IIA, but not the neutralizing anti-HMGB1 antibody, significantly inhibited TNBS-induced spinal TLR4 and GFAP expression. LIMITATIONS: In addition to TLR4, HMGB1 can also bind to toll-like receptor-2 (TLR2) and the receptor for advanced glycation end products (RAGE). Additional studies are warranted to ascertain whether HMGB1 contributes to CP-induced pain through activation of these receptors. CONCLUSIONS: Our results suggest that spinal HMGB1 contributes to the development of CP-induced pain and can potentially be a therapeutic target. TSN IIA attenuates CP-induced pain via downregulation of spinal HMGB1 and TRL4 expression. Therefore, TSN IIA may be a potential anti-nociceptive drug for the treatment of CP-induced pain.


Subject(s)
Benzofurans/therapeutic use , HMGB1 Protein/biosynthesis , Pain/drug therapy , Pain/etiology , Pancreatitis, Chronic/complications , Toll-Like Receptor 4/biosynthesis , Animals , Antibodies, Blocking/administration & dosage , Antibodies, Blocking/therapeutic use , Benzofurans/administration & dosage , Cytokines/metabolism , Down-Regulation/drug effects , Glial Fibrillary Acidic Protein/biosynthesis , Glial Fibrillary Acidic Protein/genetics , HMGB1 Protein/genetics , Hyperalgesia/drug therapy , Hyperalgesia/etiology , Injections, Intraperitoneal , Injections, Spinal , Neuralgia/drug therapy , Neuralgia/genetics , Pain Measurement , Pancreatitis, Chronic/chemically induced , Pancreatitis, Chronic/pathology , Rats , Rats, Sprague-Dawley , Toll-Like Receptor 4/genetics , Trinitrobenzenesulfonic Acid
4.
Immunol Lett ; 119(1-2): 91-6, 2008 Aug 15.
Article in English | MEDLINE | ID: mdl-18579220

ABSTRACT

CD27, which belongs to the TNF receptor family, is a costimulatory molecule that participates in T-cell activation. Unlike costimulatory molecules such as OX40 and 4-1BB, little is known about the role CD27 plays a role in the development of experimental diseases. We asked whether CD27 and its ligand CD70 participate in the development of experimental allergic conjunctivitis (EC) in BALB/c mice, which is generated by immunization with ragweed (RW) in alum and challenged 10 days later with RW in eye drops. The roles of CD27 and CD70 were tested by intraperitoneally injecting the mice with anti-CD27, anti-CD70 or a control Ab during the induction or effector phase. Twenty-four hours after challenge, the conjunctivas, blood and spleens were harvested for histological analysis, measuring Ig levels and cytokine analysis, respectively. Regardless of when the mice were treated, anti-CD27 or anti-CD70 Ab treatment did not significantly affect the severity of EC as evaluated by conjunctival eosinophil numbers. However, anti-CD27 or anti-CD70 Ab treatment during the induction phase did significantly modulate systemic humoral and cellular immune responses. In vitro treatment of RW-primed splenocytes with anti-CD27 or anti-CD70 Ab did not affect the EC-inducing capability of the splenocytes. Taken together, CD27 and CD70 do not play a critical role in the development of EC.


Subject(s)
Allergens/immunology , Ambrosia/immunology , CD27 Ligand/immunology , Conjunctivitis, Allergic/immunology , Eosinophils/immunology , Pollen/immunology , Tumor Necrosis Factor Receptor Superfamily, Member 7/immunology , Adoptive Transfer , Alum Compounds/administration & dosage , Animals , Antibodies, Blocking/administration & dosage , CD27 Ligand/metabolism , Cell Extracts , Conjunctivitis, Allergic/etiology , Conjunctivitis, Allergic/physiopathology , Cytokines/metabolism , Eosinophils/cytology , Eosinophils/drug effects , Lymphocyte Activation/drug effects , Mice , Mice, Inbred BALB C , Rhinitis, Allergic, Seasonal/immunology , Severity of Illness Index , Tumor Necrosis Factor Receptor Superfamily, Member 7/metabolism , Vaccination
5.
J Immunol ; 178(11): 6894-900, 2007 Jun 01.
Article in English | MEDLINE | ID: mdl-17513738

ABSTRACT

Dendritic cells are believed to play an essential role in regulating the balance between immunogenic and tolerogenic responses to mucosal Ags by controlling T cell differentiation and activation via costimulatory and coinhibitory signals. The CD28/CTLA-4-CD80/CD86 signaling pathway appears to be one of the most important regulators of T cell responses but its exact role in responses to orally administered proteins remains to be elucidated. In the present study, the involvement of the CD28/CTLA-4-CD80/CD86 costimulatory pathway in the induction of allergic sensitization and oral tolerance to peanut proteins was investigated. In both an established C3H/HeOuJ mouse model of peanut hypersensitivity and an oral tolerance model to peanut, CD28/CTLA-4-CD80/CD86 interactions were blocked using the fusion protein CTLA-4Ig. To examine the relative contribution of CD80- and CD86-mediated costimulation in these models, anti-CD80 and anti-CD86 blocking Abs were used. In the hypersensitivity model, CTLA-4Ig treatment prevented the development of peanut extract-induced cytokine responses, peanut extract-specific IgG1, IgG2a, and IgE production and peanut extract-induced challenge responses. Blocking of CD80 reduced, whereas anti-CD86 treatment completely inhibited, the induction of peanut extract-specific IgE. Normal tolerance induction to peanut extract was found following CTLA-4Ig, anti-CD86, or anti-CD80 plus anti-CD86 treatment, whereas blockade of CD80 impaired the induction of oral tolerance. We show that CD28/CTLA-4-CD80/CD86 signaling is essential for the development of allergic responses to peanut and that CD86 interaction is most important in inducing peanut extract-specific IgE responses. Additionally, our data suggest that CD80 but not CD86 interaction with CTLA-4 is crucial for the induction of low dose tolerance to peanut.


Subject(s)
Allergens/administration & dosage , Antigens, CD/physiology , Antigens, Differentiation/physiology , Arachis/immunology , B7-1 Antigen/physiology , CD28 Antigens/physiology , Food Hypersensitivity/immunology , Immune Tolerance/immunology , Signal Transduction/immunology , Abatacept , Administration, Oral , Allergens/immunology , Allergens/metabolism , Animals , Antibodies, Blocking/administration & dosage , Antigens, CD/immunology , Antigens, CD/metabolism , Antigens, Differentiation/immunology , Antigens, Differentiation/metabolism , B7-1 Antigen/immunology , B7-1 Antigen/metabolism , CD28 Antigens/immunology , CD28 Antigens/metabolism , CTLA-4 Antigen , Cells, Cultured , Disease Models, Animal , Immunoconjugates/administration & dosage , Immunoglobulin E/biosynthesis , Immunoglobulin E/blood , Immunoglobulin E/physiology , Ligands , Mice , Plant Extracts/administration & dosage , Plant Extracts/immunology , Plant Extracts/metabolism , Plant Proteins/administration & dosage , Plant Proteins/immunology , Plant Proteins/metabolism
6.
Birth Defects Res A Clin Mol Teratol ; 67(10): 837-47, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14745937

ABSTRACT

BACKGROUND: Folic acid (FA) supplementation reduces neural tube defects (NTDs) by 70%. However, the cause of most NTDs cannot be attributed to folate deficiency, to mutations of genes that encode folate pathway enzymes, and folate receptors (FRs) that mediate cellular folate uptake. Mouse embryos nullizygous for the ortholog of the FRalpha gene have lethal congenital abnormalities that are preventable by administration of folinic acid to the dams. To determine whether antibodies to FRs are similarly teratogenic, we studied a rat model. METHODS: Immunohistochemistry with an antiserum to rat FRs was used to identify the receptors on reproductive tissues and embryos. Gestation day (GD) 8 rats received intraperitoneal injections of antiserum to the FRs, and their embryos were examined 2-9 days later. Some rats received pharmacologic doses of folinic acid or dexamethasone before the antiserum was administered. RESULTS: The FRs are present on oocytes, the oviduct, and uterine epithelial cells, and in the embryo at all stages examined between GD4 and GD15. The antiserum has a dose-related effect on embryo viability and organogenesis. Folinic acid prevented teratogenicity resulting from smaller doses of antiserum, but not that caused by larger doses. Resorption of embryos with the larger doses of the antiserum was prevented by dexamethasone. CONCLUSIONS: FRs are expressed on oocytes, epithelial cells of reproductive organs, and embryonic and extraembryonic tissues. Antiserum to FRs administered to pregnant rats causes embryonic damage. Embryo lethality with smaller doses of antiserum is preventable by administration of folinic acid, while larger doses cause embryo damage by immune-mediated cell lysis, which can be prevented by dexamethasone.


Subject(s)
Antibodies, Blocking/pharmacology , Autoantibodies/immunology , Carrier Proteins/immunology , Embryonic and Fetal Development/drug effects , Receptors, Cell Surface/immunology , Animals , Antibodies, Blocking/administration & dosage , Antibody Specificity , Carrier Proteins/metabolism , Dexamethasone/pharmacology , Disease Models, Animal , Dose-Response Relationship, Immunologic , Drug Therapy, Combination , Embryonic and Fetal Development/immunology , Female , Folate Receptors, GPI-Anchored , Folic Acid/immunology , Injections, Intraperitoneal , Leucovorin/pharmacology , Pregnancy , Rats , Rats, Sprague-Dawley
7.
Brain Res ; 889(1-2): 239-42, 2001 Jan 19.
Article in English | MEDLINE | ID: mdl-11166711

ABSTRACT

Our study corroborated previous findings on the distribution of ANP and co-localization of ANP and OT in hypothalamic magnocellular neurons. We detected ANP/OT in smaller cells which apparently corresponded to parvocellular neurons and additionally a massive group of ANP immunoreactive fibers from periventricular regions to the median eminence, here closely associated with oxytocinergic fibers originated from PVN. ANP immunoneutralization did not change the basal OT level but blocked the OT secretion normally induced by osmotic stimulus. Thus, endogenous hypothalamic ANP seems necessary to stimulate OT release in the hyperosmolality condition.


Subject(s)
Atrial Natriuretic Factor/physiology , Hypothalamus/physiology , Oxytocin/metabolism , Animals , Antibodies, Blocking/administration & dosage , Antibodies, Blocking/pharmacology , Atrial Natriuretic Factor/antagonists & inhibitors , Hypothalamus/cytology , Hypothalamus/metabolism , Immunohistochemistry , Injections, Intraventricular , Male , Median Eminence/metabolism , Neurons/metabolism , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL